2nd Jul 2020 11:18
(Alliance News) - Chepstow, Wales-based Creo Medical Group PLC on Thursday said it has secured a loan of GBP2.0 million from Cardiff Capital Region to develop a new method of sterilisation to kill bacteria and viruses, possibly including Covid-19.
Creo, a medical device company focused on the emerging field of surgical endoscopy, believes that the new product, named Creo's Cool Plasma technology, has the potential for both medical and non-medical applications.
Creo said, "...the technology has the potential for use in wound care, medical device sterilisation, PPE sterilisation, endoscope sterilisation to kill the bacteria associated with urinary tract infections, as well as general sterilisation and cleaning of enclosed environments within the service and transport sectors."
The five-year loan will help with the creation of Creo's Plasma division, which aims to create safe environments through sterilisation and decontamination.
The technology has been shown to be effective against bacteria including MRSA and E.Coli. This means that it is likely to be effective against Covid-19, "given its performance on relatively 'tougher' bacteria," the company said.
Creo is currently working with partners, including University College Hospital in London, University of the West of England in Bristol, National Institute for Health Research and The Griffin Institute at Northwick Park.
Creo's shares were up 0.8% at 210.74 pence each on Thursday morning in London.
By Greg Roxburgh; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Creo Medical